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1. Introduction 
Pulmonary hypertension (PH) was first described over 100 years ago, but a thorough 
understanding of its pathogenesis and a successful approach to curing the disease still 
remain under investigation. 
Advanced research in the field of PH has enhanced our understanding of this entity and has 
led to new therapies. PH is rare but can affect people of all ages and is associated with 
several seemingly unconnected diseases. 
2. Definition 
PH refers to increased pressure in the arterial site of the pulmonary circulation and is 
defined as persistent elevation of mean pulmonary arterial pressure (MPAP) above 25 
mmHg.  
The current hemodynamic definition of PH is described in Table 1. The first clinical 
classification of PH was proposed at the first international conference on primary 
pulmonary hypertension endorsed by the World Health Organization (Hatano & Strassert, 
1975). The previous version of the European Society of Cardiology (ESC) PH guidelines 
adopted the Evian-Venice classification proposed at the second and third World meeting on 
PH in 1998 and 2003 respectively (Galiè et al., 2004). According to these classifications, 
clinical conditions associated with PH are divided in five groups according to pathological, 
pathophysiological and therapeutic characteristics. During the fourth World symposium on 
PH held in Dana Point, California, the consensus agreement of experts worldwide was to 
maintain the general philosophy and organization endorsed by the Evian-Venice 
classifications while at the same time amending some specific points so as to improve clarity 
and to take into account new information (Galiè et al., 2009). Accordingly, PH can be 
classified into six clinical groups with specific characteristics (Table 2). 
Anesthesiologists encounter patients with PH in a variety of situations in the operating 
room (Tidswell & Higgins, 2007). The most common underlying pathology of cardiac 
surgery patients which leads to PH is due to left-sided valvular heart disease, left-sided 
ventricular heart disease and shear stress from increased pulmonary blood flow due to 
intracardiac shunts. 
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Definition Characteristics Clinical group(s) 
PH MPAP 25 mmHg All 
Pre-capillary PH MPAP 25 mmHg 
PCWP 15 mmHg 
CO normal or reduced 
1. Pulmonary arterial 
hypertension 
3. PH due to lung diseases 
4. Chronic 
thromboembolic 
pulmonary 
hypertension 
5. PH with unclear and-or 
multifactorial 
mechanisms 
Post-capillary PH 
 
 
Passive 
Reactive (out of proportion) 
MPAP 25 mmHg 
PCWP 15 mmHg 
CO normal or reduced 
TPG 12 mmHg 
TPG >12 mmHg 
2. PH due to left heart 
disease 
Table 1. Hemodynamic definition of pulmonary arterial hypertension.  
CO, cardiac output; MPAP, mean pulmonary arterial pressure; PH, pulmonary hypertension; 
PCWP, pulmonary capillary wedge pressure; TPG, transpulmonary pressure gradient (MPAP- 
PCWP) 
Data from the multinational database EuroSCORE have demonstrated that PH is an 
independent risk factor for increased morbidity and mortality in patients undergoing heart 
surgery (Roques et al., 1999). 
3. Pathophysiology 
Highlighting the pathophysiology of PH can help us properly manage acute PH in the 
specific context of cardiac surgery. 
The cause of PH in the case of mitral or aortic valve disease, especially when PH is a 
complication of stenotic valve disease, is quite complex. Increased left arterial pressures 
result in chronic obstruction to venous drainage in the pulmonary vasculature, causing 
remodeling of the pulmonary vascular bed and ultimately PH.  
The molecular pathophysiological mechanism of PH has been recently reviewed. The PH 
‘phenotype’ is characterized by endothelial dysfunction, a decrease ratio of apoptosis / 
proliferation in the pulmonary artery muscle cells and a thickened disordered adventitia 
in which there is excessive activation of adventitial metalloproteases (McLaughlin et al., 
2009).  
The fundamental functions of the endothelium include: regulating the vascular tone, 
coordinating vascular cell growth, controlling inflammatory and immunological processes 
as well as maintaining the balance between thrombotic and fibrotic activities. Each of 
these functions is controlled by a finely tuned network of activating and inhibiting 
compounds.  
In the case of PH, the endothelium is characterized by increased production of 
vasoconstrictor / mitogenic mediators, such as endothelin and thromboxane, and deficient  
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1. Pulmonary arterial hypertension (PAH)
1.1 Idiopathic 
1.2 Heritable 
1.2.1 BMPR2 
1.2.2 ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
1.2.3 Unknown 
1.3 Drugs and toxins induced 
1.4 Associated with 
1.4.1 Connective tissue diseases 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1.4.6 Chronic hemolytic anemia 
1.5 Persistent pulmonary hypertension of the newborn 
1a. Pulmonary venoocclusive disease and-or pulmonary capillary hemangiomatosis 
2. Pulmonary hypertension due to left heart disease 
2.1 Systolic dysfunction 
2.2 Diastolic dysfunction 
2.3 Valvular disease 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension 
5. Pulmonary hypertension with unclear and-or multifactorial mechanisms 
5.1 Hematological disorders: myeloproliferative disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis, 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4 Others: Tumoural obstruction, fibrosing mediastinitis, chronic renal failure on 
dialysis 
Table 2. Updated clinical classification of pulmonary hypertension (Dana Point, 2008). 
ALK-1, activin receptor-like kinase 1 gene; BMPR2, bone morphogenetic protein receptor, type 2; 
HIV, human immunodeficiency virus 
 
production of vasodilators, such as prostacyclin (Christman et al., 1992; Giaid et al., 1993; 
Stewart et al., 1991). Elevated levels of fibrinopeptide A and plasminogen activator 
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inhibitor-1 and reduced levels of tissue plasminogen activator contribute to a procoagulant 
state. Endothelial injury may also expose the underlying smooth muscle cells to circulating 
mitogens and growth factors that stimulate cell proliferation. 
The so-called endothelium-dependent mechanism is that receptors located on the surface of 
the endothelial cells react to various stimulators or mediators and subsequently change 
signals. Via a cascade of reactions, the presence of shearing forces or mediators such as 
bradykinine and acetylcholine leads to the formation of so-called second messenger 
substances such as cyclic adenosine monophosphate (cAMP) or guanosine monophosphate 
(cGMP). These substances exert vasodilator effects and are responsible for smooth muscle 
relaxation. 
Nitric oxide (NO) is a vasodilator and inhibitor of platelet activation and vascular smooth 
muscle proliferation. The effects of NO are mediated by cGMP, which is rapidly inactivated 
by phosphodiesterase.  
Vascular dilatation occurs via the NO-triggered proliferation of endothelial-dependent 
hyperpolarizing factors which, through the activation of tension dependent potassium 
channels leads to relaxation of the smooth muscle cell. NO leads to an increase in the 
production of prostacyclin. Other potassium channels (ATP-dependent, Ca++ - dependent) 
are also involved in the regulation of the myosin-actin-calcium interaction.  
On the contrary, hypoxia or specific mediators (e.g. thrombin, metabolites of arachidonic 
acid, angiotensin II and endothelin) lead to vasoconstriction. They also function through 
signal transduction via various receptors on the endothelial cells themselves or on the 
smooth muscle cells. 
Prostacyclin and thromboxane A2 are major arachidonic acid metabolites. Prostacyclin is a 
potent vasodilator, inhibits platelet activation and has antiproliferation properties, whereas 
thromboxane A2 promotes proliferation and platelet activation In PH, the balance between 
the two molecules is shifted towards thromboxane A2. 
Endothelin-1 (ET-1) is a potent vasoconstrictor produced by endothelial cells, which 
exerts potent vasoactive properties by binding to specific receptors (ETA and ETB) on 
vascular endothelial and smooth muscle cells. Following the bonding of ET-1 to the ETA 
receptor, phospholipase C is activated which consecutively leads to the accumulation of 
inositol-triphosphates and intracellular calcium. Through this mechanism, 
vasoconstriction as well as cell proliferation take place in various tissues. Activation of the 
ETB receptor upon the endothelial cells not only leads to the release of NO and 
prostacyclin and consequence vasodilatation, but also inhibits expression of the 
endothelin converting enzyme upon endothelial cell and apoptosis. Pulmonary clearance 
of circulating ET-1 as well as its reentrance into the endothelial cells is also regulated via 
these receptors.  
Serotonin (5-hydroxytryptamine, 5-HT) (Jain et al., 2007) is a pulmonary vasoconstrictor 
and promotes pulmonary artery smooth muscle cells hypertrophy and hyperplasia. There is 
a transporter for 5-HT that controls serotonin uptake and clearance, which is located on the 
surface of platelets, neurons, and pulmonary endothelial cells. The presence of elevated 
levels of 5-HT in the blood of patients with PH suggests that this substance also plays a role 
in the pathogenesis of PH. 
In summary, PH can simply be explained as a functional disturbance of the endothelium, 
caused by an imbalance between the dilative and contractive mechanisms within the 
vascular resistance of the pulmonary vascular bed. These functional changes occur together 
with morphological alterations within the pulmonary vasculature.  
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Thus, NO, endothelin and prostacyclin also have a direct influence upon the thrombocytes, 
the endothelial-leukocyte interaction as well as vascular cell proliferation. This imbalance 
leads to thrombotic tendency, vasoconstriction and proliferation. 
3.1 Pathophysiology of post bypass exacerbation of PH 
Post bypass pulmonary vasoconstriction has been demonstrated in a variety of experimental 
models as well as in the clinical setting and there is increased evidence that the severity of 
the vasoconstriction correlates with the extent of cardiopulmonary bypass (CPB)-induced 
endothelial injury (Riedel, 1999). 
Endothelial injury and dysfunction is promoted by acidosis, hypoxia, shear stress from 
increased pulmonary blood flow (left-to-right intracardiac shunts), and fibrin from 
thromboembolism. Leukocyte activation, oxygen free radicals such as superoxide, hydroxyl 
radicals and peroxynitrate, tumor necrosis factor ┙, interleukin-1, elastases and 
inflammatory mediators are involved in this process. 
The most important mechanism underlying this endothelial dysfunction in the setting of 
cardiac surgery could be ischemia/reperfusion injury, with associated inflammatory cell 
and complement activation. Ischemia/reperfusion injury due to inadequate flow in the 
bronchial circulation plays a pivotal role in the exacerbation of post-CPB PH (Matuschak, 
1999). 
In summary, intraoperative pulmonary vasoconstriction  is a result of complex interactions 
between various perioperative factors: preoperative status of the pulmonary vascular bed 
(valvular pathology, shear stress), intraoperative vasospastic stimuli (hypoxia, hypercarbia, 
acidosis, ischemia/reperfusion injury, inflammatory mediators, free radical formation, 
pulmonary leukosequestration, excess thromboxane or endothelin production and 
microemboli) and postoperative factors (atelectasis, adrenergic tone, hypoxic pulmonary 
vasoconstriction). Preexisting pulmonary hypertension, increased pulmonary blood flow 
states, in combination with intraoperative hypoxia, acidosis, hypothermia, and 
microembolism may exacerbate CPB-induced pulmonary hypertension. 
The final result of this pathophysiology is the imbalance between vasoconstrictor and 
vasodilator factors at the pulmonary vascular bed, that is reduction in prostacyclin (PGI2) 
and NO levels and an increase in thromboxane A2, catecholamines, adhesion molecules and 
endothelin levels.  
This can culminate to a life- threatening situation and disconnecting the patient from the 
extracorporeal circulation may prove particularly laborious, because of right ventricular 
failure.  
Moreover, after discontinuation from bypass there is need for heparin reversal and this is 
accomplished by the administration of protamine. Protamine administration is commonly 
associated with hypotension due to systemic vasodilatation. This is suggested to be 
mediated by the release of NO (Raikar, 1996). A rare reaction brought about by protamine 
administration, which may be mediated by the release of complement pathway 
anaphylatoxins (C3a and C5b) and / or cyclooxygenase products (e.g. thromboxane A2), 
may lead to catastrophic pulmonary hypertension and subsequent right ventricular failure. 
4. Clinical impact of post bypass exacerbation of PH 
Independent of the exact cause, the exacerbation of preexisting PH can lead to a further 
increase in the right ventricular afterload and distension of an already dysfunctional right 
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ventricle, resulting in increased right ventricular free wall tension and myocardial oxygen 
consumption. 
Normally, the pulmonary circulation is a low pressure, high flow vascular bed 
accommodating the entire cardiac output with each heartbeat. Elevated pulmonary 
vascular resistance (PVR) may significantly contribute to right ventricular dysfunction, 
which may compromise the preload of the left ventricle inducing systemic hypotension. 
In patients with pathologically increased PVR, the right ventricle and left ventricle are 
interdependent and have similar vitally important functions. Right ventricular dilatation 
causes shifting of the intraventricular septum towards the left ventricle, leading to a 
smaller underfilled left ventricular cavity. The normal thin walls and crescent shape of the 
right ventricle result in a highly compliant right ventricular chamber, which is able to 
accommodate large increases in volume. However, the right ventricular adaptive 
mechanisms are not well suited to acute, large increases in pressure, (Fischer et al., 2003), 
as this may happen after CPB. 
Furthermore systemic hypotension decreases right ventricular coronary perfusion pressure 
and oxygen delivery. Therefore, a vicious circle starts that can lead to exacerbation of right 
ventricular dysfunction.  
5. Diagnosis of PH 
The existence of sophisticated monitoring in this particular group of patients is deemed 
necessary because early diagnosis and prompt institution of therapy for acute PH is 
required in order to prevent right ventricular failure. 
Diagnosis is aided by awareness of existing preoperative risk factors, such as valvular 
pathology or intracardiac shunts that are associated with PH. The development of acute PH 
will result in clinical signs of relatively rapid onset relating to the development of tricuspid 
regurgitation: prominent central venous atrioventricular pulsatile pressure waveforms, 
right-sided heart failure and a holosystolic murmur at the lower border of the sternum that 
increases in intensity during inspiration. 
Pulmonary artery pressure catheterization and transesophageal echocardiography (TOE) 
constitute a valid monitoring tool for early detection of acute PH. 
Pulmonary artery pressure catheterization will demonstrate elevated right atrial pressure, 
right ventricular end-diastolic pressure and pulmonary artery pressure with normal or low 
pulmonary wedge pressures. In the case of right ventricular dysfunction without 
pulmonary vasoconstriction, the pulmonary artery pressure may also be normal. 
Hemodynamic parameters calculated and derived by thermodilution will reflect elevated 
PVR and a reduction in right ventricular stroke work index and right ventricular stroke 
work index / central venous pressure relationship and a reduction in cardiac output or right 
ventricular ejection fraction. 
TOE is an invaluable tool in the diagnosis of PH and right ventricular dysfunction, 
demonstrating both right ventricular volume and pressure overload. The two- dimension 
mode provides a subjective view of the increased ratio of right ventricle-to- left ventricle 
chamber size, paradoxical septal bulging, and deterioration in right ventricular function as 
seen on five-chamber and 4-chamber long axis views (Figure 1). 
Color flow mapping will often reveal pulmonary and tricuspid regurgitation. The use of 
continuous wave Doppler across the regurgitant tricuspid valve allows quantification of the 
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Fig. 1. Severe tricuspid regurgitation and enlargement of the right ventricle caused by severe 
pulmonary hypertension 
 
pressure gradient across the valve and thereby an estimation of the pulmonary artery 
pressure. 
Also TOE has been proved to be a useful tool in the continuous assessment of the results of 
the applied therapeutic strategy. 
6. Treatment of PH 
Therapeutic strategies should be aimed at the prevention of acute perioperative PH or at the 
prevention of further increases in the already existing PH. The cornerstone of treatment lies 
in prevention of right ventricular failure brought about by the abrupt increase of right 
ventricular afterload, since impaired RV function is associated with poor outcome in the 
surgical and non-surgical setting. 
It is important to underline that the treatment of perioperative PH in cardiac surgery 
patients should start as promptly as possible. If clinicians do not react early, a vicious circle 
may start and the discontinuation from CPB may prove extremely difficult. Right 
ventricular failure and low cardiac output can occur several hours after weaning from CPB, 
so a high level of vigilance is required during the entire postoperative period. 
The incidence of postoperative acute refractory right ventricular failure is only about 0.1% 
after cardiotomy, but this can rise to around 2-3% after heart transplantation and even to 20-
30% when a left ventricular assist device has been implanted  (Kaul & Fields, 2000). 
The appropriate treatment in order to prevent right ventricular failure is based on the 
following principles (Winterhalter et al., 2010):  
 
 Avoidance of factors that are well known to exacerbate PH, such as hypoxemia, 
hypercarbia, acidosis, hypervolemia, hypothermia, and light anesthesia. 
 Optimization of right ventricular preload: If the right atrial pressure is low, volume 
infusion is indicated. If it is high, diuretics and nitroglycerin are preferable.  
 Improvement of right ventricular contractility: The administration of inotropes, such as 
epinephrine, dobutamine or the phosphodiesterase-3-inhibitor milrinone may be useful 
to raise right ventricular contractility.  
 Minimization of right ventricular afterload: This can be accomplished by different 
strategies. The use of intravenously or inhalable vasodilators such as milrinone, 
nitroprusside, NO or the stable prostacyclin analogue iloprost can be administered. 
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Readministration of heparin and postoperative reinstitution of CPB may be necessary in 
refractory cases.  
6.1 Intravenous vasodilators 
The main goal of pulmonary vasodilatation is to lower right ventricular impedance, so as to 
decrease afterload and thus improve ventricular performance. 
Traditional methods of treatment for perioperative PH included nitrates, prostaglandins, 
phospodiesterase -3 inhibitors and calcium channel blockers. The aforementioned 
therapeutic modalities represent three distinct pharmacological pathways. 
Nitrates (sodium nitroprusside-SNP, nitroglycerin-NTG) are NO donors, releasing NO 
spontaneously, which is normally located in biological tissues. Both agents decrease PVR, 
but because of their nonselectivity, they often decrease systemic blood pressure to a degree 
that impairs right ventricular perfusion and can cause ischemia. 
Normally, the right ventricle is perfused during the entire cardiac cycle. In the presence of 
PH, the hypertrophic right ventricle generates elevated intracavital and intramural 
pressures, limiting the period of perfusion predominantly to diastole, thereby increasing the 
risk of right ventricular ischemia and failure in the presence of systemic hypotension. 
Therefore, nitrates can compromise right ventricular perfusion through their hypotensive 
action in the arterial part of the circulation. Furthermore, these drugs increase venous 
admixture by dilatation of pulmonary vessels supplying poorly ventilated alveoli and 
therefore abolishing the protective effect of hypoxic pulmonary vasoconstriction. 
Prostacyclins (prostacyclin PGI2, prostaglandin-E1 PGE1) have been reported to have 
beneficial effects on pulmonary artery pressure and right ventricular function 
perioperatively. They act by stimulating adenylate cyclase to generate cAMP, but they also 
act non-selectively when administered intravenously and systemic hypotension limits their 
clinical effectiveness. 
Phosphodiesterase-3 inhibitors (whose milrinone is the major representative) cause 
vasodilatation via inhibition of enzyme phosphodiesterase-3, increasing cAMP, which 
causes vasodilatation.  
Calcium channel blockers also induce systemic vasodilatation but without sparing the 
systemic circulation. 
Due the lack of selectivity to the pulmonary circulation of the aforementioned agents and 
the risk of a massive drop in the systemic blood pressure and right ventricular perfusion 
pressure, their administration should be avoided (Kieler-Jensen et al., 1993). 
On the other hand, the importance of inhalable vasodilators has risen continuously over 
recent years. The advantage of these inhalable substances is their pulmonary selectivity and 
the subsequent reduction of systemic side effects, such as systemic hypotension. Also, the 
probability of ventilation-perfusion mismatch is low, as by inhalation primarily blood 
vessels close to the ventilated alveoli are dilated. The risks of shunt development and severe 
hypoxia are thus eliminated (Walmrath et al., 1997). 
6.2 Inhalable vasodilators 
The administration of inhalable pulmonary vasodilators, such as inhaled nitric oxide (NO), 
prostaglandins, NO donors (SNP-NTG) and milrinone is preferable over intravenous agents 
because of their pulmonary selectivity which is exerted without a concurrent increase in 
shunt fraction. 
Inhaled NO: NO stimulates soluble guanylate cyclase (sGC) and increases cGMP. The latter 
activates cGMP- dependent protein kinases that are abundant in the cerebellum, smooth and 
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cardiac myocytes, platelets, and leukocytes (Lucas et al., 2000). In turn, these kinases 
mediate a cGMP-induced decrease in intracellular calcium concentration in vascular smooth 
muscle and vasodilatation (Hanafy et al., 2001). 
Inhaled NO is a selective pulmonary vasodilator without clinically significant effect on 
blood pressure and cardiac output. Its selective action results from the fixation of NO to 
the heme moiety of the hemoglobin molecule after passing through the pulmonary vessel 
wall. NO is then oxidized to nitrogen dioxide (NO2) and nitrogen trioxide (NO3). 
Hemoglobin is transformed to methemoglobin, which is secondarily reduced to 
hemoglobin by methemoglobin reductase. Although NO has no systemic hemodynamic 
effects, it does have extrapulmonary activity (Wang et al., 2003). That is, it interferes with 
platelet and leukocyte functions, fibrinolysis, and reperfusion injury by inhibiting 
expression of adhesion molecules at leukocyte surfaces and by activation of sCG, which 
lead to a rapid increase in platelet cGMP and inhibition of platelet aggregation. NO-
induced favorable effect on cardiac function is based on reduction of right ventricular 
afterload. Even in patients with severe right ventricular dysfunction, NO improves 
cardiac output and right ventricular ejection fraction (Bhorade et al., 1999).Most of the 
studies used doses of 20 parts per million (ppm) (range 10-40 ppm). It is reasonable to 
start NO at the lowest possible dose and titrate upwards as required in patients with 
pulmonary hypertension. 
Toxicity from NO results from the formation of methemoglobin, NO2 and peroxynitrite. 
Life-threatening increases in PVR have been noted with acute withdrawal of NO. To prevent 
rebound pulmonary hypertension, NO should be tapered off progressively without any 
attempt to discontinue it completely if FiO2 is higher than 50%. However, these 
disadvantages of NO therapy have called for research on inhaled alternatives to NO. 
Prostaglandins  
 Inhaled prostacyclin (PGI2)  
Prostacyclin is a member of the prostaglandin family derived from arachidonic acid. 
Inhaled prostacyclin seems to be the more favorable agent because of its lack of toxicity, 
ease of application, and reduced cost. Similar to NO, it is produced by the vascular 
endothelium and is involved in the regulation of vascular tone and in localized thrombotic 
and inflammatory processes. PGI2 stimulates the endothelial release of NO, while NO, in 
turn, increases the synthesis of endogenous PGI2. In vivo, PGI2 is spontaneously hydrolyzed 
to its inactive metabolite 6-keto-prostaglandin-F1a with a half life of 3-6 min. 
Inhaled PGI2 produces comparable effects to NO. The two agents have been compared in 
both animal and clinical studies, which have showed that inhaled PGI2 produces greater 
decreases in PVR while NO induces greater improvements in oxygenation (Lowson, 2002). 
Moreover, Fattouch et al (Fattouch et al., 2005) have shown similar effectiveness for NO and 
inhaled prostacyclin in the treatment of pulmonary hypertension after mitral valve 
replacement in a randomized, double-blinded clinical trial. PGI2 and its metabolites are 
remarkably non-toxic compared with NO. A prominent side-effect of inhaled PGI2 is 
inhibition of platelet aggregation. Impaired in vitro platelet aggregation was noted after 2h 
of inhaled PGI2 in patients undergoing cardiac surgery, but was not associated with an 
increase in chest tubes drainage or transfusion requirements even when therapy was 
continued for 6 h (Lowson, 2002). Systemic hypotension is another potential side effect of 
inhaled PGI2, suggesting that there is a minimal absorption of inhaled PGI2 from the lungs 
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into the systemic circulation. Moreover, abrupt withdrawal of inhaled PGI2 may cause 
rebound increases in PH. (Lowson, 2002) 
Variable dose delivery, alteration of ventilation volumes, pressures, FiO2, and solvent 
evaporation with drug-concentrating effect are other obvious disadvantages. Plasma half-
life of prostacyclin is 3 to 6 minutes. 
 Iloprost  
Iloprost is a more stable carbacyclin derivative of prostacyclin and can be administered 
intermittently, as the hemodynamic effects of a single dose are sustained for approximately 
60-120 min, although the plasma half-life time of intravenously administered iloprost is 
known to be between 20-30 min (Theodoraki et al., 2002). This form of treatment appears to 
be promising combining the advantages of NO and the lack of problems of intravenous 
administration. Iloprost causes a significant reduction in MPAP and PVR and a significant 
increase in cardiac output after its administration since there is a substantial reduction in 
right ventricular afterload. It cannot be ruled out that a decrease in systemic vascular 
resistance (SVR) may occur during its administration but not to a degree that can affect 
arterial blood pressure dramatically. 
Aerosolized iloprost has been described as a more potent pulmonary vasodilator than NO in 
patients with PH (Winterhalter et al., 2008).  Its longer half-life firstly confers effective 
protection against the rebound phenomenon and, secondly, may facilitate the 
pharmacological effective transfer of the inhaler material from the pulmonary into the 
systemic arterial circulation. 
Iloprost remains stable at room temperature and does not undergo any molecular changes 
on exposure to light, in comparison to PGI2 (Fattouch et al., 2003). Also, inhaler iloprost can 
be rapidly and simply administered intraoperatively, irrespective of ventilator type. Unlike 
the situation with NO, inhaled iloprost treatment can also be continued with an ultrasonic 
nebulizer during weaning from the ventilator and after extubation. 
Episodes of PH during heart transplantation procedures can be successfully treated with the 
administration of iloprost without unwanted side effects or significant systemic impact 
(Theodoraki et al., 2006). 
Right heart failure after left ventricular assist device (LVAD) implantation is an acute life-
threatening event. In patients with intraoperative severe acute right heart failure after 
implantation of a LVAD, successful weaning from CPB was possible after inhaled iloprost 
was added (Winterhalter et al., 2006). 
In addition to its beneficial hemodynamic profile, aerosolized iloprost also exerted beneficial 
effects on arterial oxygenation, which probably reflected the more potent effects of iloprost 
on the pulmonary vascular bed and the more pronounced increase of mixed-venous oxygen 
saturation (Hoeper et al., 2000). 
 NO donors 
Inhaled NTG decreases PH without producing systemic vasodilatation (Yurtseven et al., 
2003). Further studies are warranted to define their potential utility because nebulization of 
these drugs does not require an expensive apparatus like the one required for NO 
nebulization. 
 Phosphodiesterase – 3 inhibitors 
Milrinone inhibits the breakdown of cAMP, thereby promoting pulmonary vasodilatation. 
There are few recent studies which demonstrated the beneficial effects of inhaled milrinone 
on PH during weaning of patients from CPB.  
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Inhaled milrinone prevents pulmonary endothelial dysfunction after CPB, and its 
hemodynamic and oxygenation profiles are safer than those of intravenous milrinone 
(Lamarche et al., 2005). 
6.2 Combination therapy 
NO and PGI2 / iloprost cause vasodilatation via two different intracellular signal pathways 
by relaxing smooth muscle cells. After diffusion into the smooth muscle cells, NO causes 
vascular smooth muscle cell relaxation by stimulating guanylate cyclase, leading to an 
increase in 3,5-cGMP and a reduction in intracellular calcium concentration. By contrast, 
PGI2 / iloprost result in an increase in intracellular cyclic 3,5 cAMP concentrations, causing 
calcium-activated potassium channels to open through activation of adenyl-cyclase. 
However these drugs can be administered as combination therapy. 
6.3 Other drugs 
Adenosine activates adenylate cyclase and stimulates the generation of cAMP. Adenosine is 
rapidly inactivated with a plasma half-life of less than 10 seconds. In a study performed on 
ten patients who received an infusion of low-dose adenosine (50 mg/Kg/min) after 
weaning from CPB a significant reduction in MPAP and PVR and an increase in CO were 
demonstrated without adverse side effects without any adverse side effects (Fullenrton et 
al., 1996). 
Phosphodiesterase-5-inhibitors such as zaniprast, dipyridamole, and sildenafil have been 
studied in the field of PH. There have been reports of variable beneficial effects of these 
agents on PH after cardiac surgery in combination with NO (Ichinose et al., 2001). 
Bosentan is an endothelin antagonist which does not act acutely but has shown promising 
results as a sole agent and as combination chronic therapy for PH (Channick et al., 2004).  
7. Special aspects of PH 
7.1 PH in children 
PH in children is associated with significant perioperative risk for major complications, 
including pulmonary hypertensive crisis and cardiac arrest (Friesen & Williams, 2008). 
The goals of balanced and cautious anesthetic management are to provide adequate 
anesthesia and analgesia for the surgical procedure while minimizing increases in PVR and 
depression of myocardial function. 
The development of the aforementioned specific pulmonary vasodilators has led to 
significant advances in the medical therapy of PH that can be incorporated in the anesthetic 
management of the pediatric population. 
The incidence of complications in children with PH undergoing cardiac catheterization was 
found to be independent of the method of airway management. Tracheal intubation has 
been reported to precipitate pulmonary hypertensive crisis and death in critically ill 
pediatric patients with severe PH, so many anesthesiologists avoid intubation. Similarly, 
deep extubation can decrease exposure to noxious airway stimulation following selected 
procedures. 
However, similarly to adult patients, PVR can be affected by many other aspects of 
anesthesia technique such as the inspired oxygen concentration, acid-base management, 
ventilation mode, drugs, blood products, CPB, pain management and stress response. 
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Given the multiple factors involved, it is not surprising that no single anesthetic agent has 
been shown to be ideal for that particular patient population and therefore, balanced 
anesthesia is preferred. 
7.2 Anesthetic drugs 
Numerous studies (Fischer et al., 2003; Blaise et al., 2003) investigate the effect of anesthetic 
drugs on pulmonary vascular tone. In general, it appears that the effect of anesthetic agents 
on the pulmonary circulation is different from their effect on the systemic circulation, often 
resulting in an increase in PVR. 
Propofol decreases PAP, PVR as well as mean arterial pressure (MAP) after CPB. Propofol 
infusion to children undergoing cardiac catheterization decreased SVR significantly and 
cardiac contractility mildly. In addition, patients with cardiac shunts and fixed elevated PVR 
(Eisenmenger syndrome) may experience oxygen desaturation because the decrease in SVR 
will augment right-to-left shunt. 
Etomidate is known for its lack of systemic hemodynamic effects on patients with heart 
disease, but its pulmonary vascular effects have not been investigated adequately.  
Thiopental has been reported to increase PVR in adults, but in children a decrease of PVR by 
thiopental has been reported. However, thiopental is a less desirable choice for patient with 
PH, because it can cause significant myocardial depression and systemic hypotension. 
An increase in PVR has been observed with Ketamine during spontaneous ventilation, but 
decreases in PVR have been reported during controlled ventilation. This effect makes 
ketamine the drug of choice for the anesthetic management of patients with PH, particularly 
of children with congenital heart diseases. 
Benzodiazepines are associated with minimal hemodynamic effects and are considered useful 
for preanesthetic premedication. 
Fentanyl and sufentanil have minimal pulmonary and systemic effects and attenuate 
pulmonary and vascular response to noxious stimuli in adults as well as in children. 
Volatile anesthetics have variable effects on pulmonary vascular tone. Isoflurane and 
halothane potentiate the vasodilator response to ┚1 adrenoceptor activation. Isoflurane, 
halothane, enflurane and desflurane (but not sevoflurane) inhibit endothelium-dependent 
relaxation by inhibiting the activity of the adenosine triphosphate-sensitive potassium 
channels, which mediate the vasodilator effect of many endogenous mediators such as 
adenosine, PGI2 and nitric oxide. In general, isoflurane and sevoflurane are associated with 
clinical pulmonary vasodilatation and are accepted components of a balanced anesthetic 
technique in patients with PH. 
However, volatile anesthetic agents can lead to dose-dependent depression of cardiac 
contractility and reduction of SVR, which may be problematic. Moreover, volatile 
anesthetics, when administered in high minimal alveolar concentrations, attenuate hypoxic 
pulmonary vasoconstriction, thereby exacerbating ventilation-perfusion mismatching. 
Nitrous oxide increases the pulmonary vascular tone in adult patients undergoing valve 
surgery preoperatively and postoperatively. In children, it has shown to have little effect on 
pulmonary hemodynamics. 
8. Conclusion 
In the present chapter, we described the pathogenesis and pathophysiology of PH as well as 
its perioperative management with specific emphasis in the period following cardiac 
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surgery. Aspects of perioperative manipulation aiming at optimizing right ventricular 
function and the application of novel therapeutic modalities were critically presented and 
evaluated. 
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